tiprankstipranks
Trending News
More News >
Spire Healthcare Group PLC (GB:SPI)
LSE:SPI
Advertisement

Spire Healthcare (SPI) AI Stock Analysis

Compare
55 Followers

Top Page

GB:SPI

Spire Healthcare

(LSE:SPI)

Rating:68Neutral
Price Target:
240.00p
▲(5.49%Upside)
Spire Healthcare's overall score reflects strong financial performance and positive corporate events. The robust revenue growth and strategic initiatives are significant positives, but high leverage and modest net profit margins pose risks. Technical indicators show neutral to slightly positive momentum, while valuation suggests the stock is priced on the higher side.

Spire Healthcare (SPI) vs. iShares MSCI United Kingdom ETF (EWC)

Spire Healthcare Business Overview & Revenue Model

Company DescriptionSpire Healthcare (SPI) is a leading private healthcare provider in the United Kingdom, offering a comprehensive range of services, including elective surgery, diagnostics, and specialized treatments. With a network of hospitals and clinics across the country, Spire Healthcare is committed to providing high-quality, patient-centered care through its team of experienced medical professionals and state-of-the-art facilities.
How the Company Makes MoneySpire Healthcare generates revenue primarily through the provision of healthcare services to privately insured, self-pay, and NHS-funded patients. The company operates a network of hospitals that offer a wide range of medical services, including elective surgeries, diagnostics, and specialized treatments. Revenue streams include payments from private medical insurance companies, direct payments from patients who choose to self-fund their treatments, and contracts with the National Health Service (NHS) for specific services. Spire Healthcare also earns income from ancillary services such as pharmacy and physiotherapy. Key factors contributing to its earnings include its reputation for quality care, strategic partnerships with insurers, and its ability to attract and retain skilled healthcare professionals.

Spire Healthcare Financial Statement Overview

Summary
Spire Healthcare shows strong revenue growth and operational efficiency, with consistent improvements in gross and EBIT margins. However, the modest net profit margin and high leverage present challenges. The balance sheet indicates substantial leverage with a high debt-to-equity ratio, and cash flow generation is robust, supporting liquidity and investments.
Income Statement
75
Positive
Spire Healthcare has demonstrated consistent revenue growth over recent years, with a significant increase from £919.9M in 2020 to £1.51B in 2024. Gross profit margin improved to 45.23% in 2024, indicating strong cost management. However, the net profit margin remains modest at 1.68%, suggesting room for improvement in overall profitability. EBIT and EBITDA margins show stable operational efficiency, with the latter at 14.06% in 2024.
Balance Sheet
65
Positive
The company maintains a relatively high debt-to-equity ratio of 1.71, reflecting substantial leverage. However, return on equity (ROE) is modest at 3.39%, indicating efficient use of equity. The equity ratio at 31.94% suggests a balanced capital structure, though increasing equity could mitigate leverage risks.
Cash Flow
70
Positive
Spire Healthcare's cash flow from operations has shown a positive trend, reaching £235.7M in 2024, supporting its capital expenditures and free cash flow generation. Free cash flow growth is steady, though the operating to net income ratio of 9.28 indicates reliance on operating performance for cash generation.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.51B1.36B1.20B1.11B919.90M
Gross Profit683.60M520.60M440.50M394.10M361.80M
EBITDA250.40M231.20M202.10M182.20M-51.90M
Net Income25.40M27.30M8.60M-9.70M-233.90M
Balance Sheet
Total Assets2.34B2.29B2.16B2.24B2.10B
Cash, Cash Equivalents and Short-Term Investments43.70M49.60M74.20M202.60M106.30M
Total Debt1.28B1.26B1.19B1.27B1.17B
Total Liabilities1.60B1.55B1.43B1.53B1.40B
Stockholders Equity748.40M739.90M731.00M709.60M706.60M
Cash Flow
Free Cash Flow123.60M115.50M72.80M101.30M95.10M
Operating Cash Flow235.70M199.90M160.50M170.60M141.70M
Investing Cash Flow-99.00M-157.20M-98.00M-48.30M-46.40M
Financing Cash Flow-145.10M-82.90M-190.90M-26.00M-79.80M

Spire Healthcare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price227.50
Price Trends
50DMA
212.26
Positive
100DMA
198.13
Positive
200DMA
210.38
Positive
Market Momentum
MACD
3.73
Positive
RSI
64.31
Neutral
STOCH
70.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SPI, the sentiment is Positive. The current price of 227.5 is above the 20-day moving average (MA) of 224.47, above the 50-day MA of 212.26, and above the 200-day MA of 210.38, indicating a bullish trend. The MACD of 3.73 indicates Positive momentum. The RSI at 64.31 is Neutral, neither overbought nor oversold. The STOCH value of 70.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SPI.

Spire Healthcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
£826.45M70.834.50%0.07%6.74%54.83%
71
Outperform
£447.67M62.242.93%125.30%40.66%-55.09%
68
Neutral
£913.38M36.033.41%101.10%11.20%-6.80%
61
Neutral
£333.95M8.4911.74%38.80%
58
Neutral
£4.85B6.57-62.36%101.97%34.03%6.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:SPI
Spire Healthcare
227.50
-13.16
-5.47%
GB:CRW
Craneware
2,340.00
22.85
0.99%
GB:PRTC
PureTech Health
142.80
-30.40
-17.55%
GB:AMS
Advanced Medical Solutions
207.50
-31.54
-13.19%

Spire Healthcare Corporate Events

Business Operations and Strategy
Spire Healthcare Appoints New Joint Corporate Broker
Positive
Jul 16, 2025

Spire Healthcare Group plc has appointed Joh. Berenberg, Gossler & Co KG, London Branch as its Joint Corporate Broker alongside J.P. Morgan Securities plc, effective immediately. This strategic appointment is expected to enhance Spire Healthcare’s market positioning and strengthen its financial advisory capabilities, potentially benefiting its stakeholders and supporting its operational growth.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Spire Healthcare Announces Change in Major Shareholdings
Neutral
Jul 10, 2025

Spire Healthcare Group PLC has announced a change in major holdings, with Harwood Capital LLP acquiring or disposing of voting rights, resulting in a total of 3.076% voting rights in the company. This notification reflects changes in shareholder positions, potentially impacting the company’s governance and influencing its strategic decisions.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £310.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Other
Spire Healthcare Directors Exercise Sharesave Plan Options
Positive
Jun 24, 2025

Spire Healthcare Group PLC announced that its Executive Directors, Justin Ash and Harbant Samra, have exercised their options under the 2022 Sharesave Plan, acquiring 1,818 shares each at an exercise price of £1.98 per share. This transaction reflects the directors’ continued confidence in the company’s growth and stability, as all acquired shares have been retained, potentially strengthening their alignment with shareholder interests.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £2.90 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Spire Healthcare Announces Change in Voting Rights
Neutral
Jun 23, 2025

Spire Healthcare Group PLC has announced a change in its voting rights, with Bridgemere Securities Limited increasing its stake to 5.5705% from a previous 4.0900%. This adjustment in voting rights could potentially impact the company’s governance and decision-making processes, influencing its strategic direction and stakeholder interests.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Executive/Board Changes
Spire Healthcare Announces New Executive LTIP Awards
Neutral
Jun 19, 2025

Spire Healthcare Group PLC has announced the grant of additional performance share awards under its Long Term Incentive Plan (LTIP) to Executive Director Harbant Samra. The awards, reflecting a recent change in his base salary, are set at 200% of his current salary and will vest based on performance conditions related to shareholder return, ROCE, hospital EBIT margin, and operational excellence. This move aligns with the company’s shareholder-approved Remuneration Policy and underscores its commitment to incentivizing leadership performance.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Regulatory Filings and Compliance
Spire Healthcare Announces Change in Major Holdings
Neutral
Jun 4, 2025

Spire Healthcare Group PLC has announced a change in its major holdings, with FIL Limited acquiring or disposing of voting rights and financial instruments. The transaction resulted in FIL Limited holding 9.105% of the voting rights in Spire Healthcare. This change in holdings could impact the company’s governance and influence decision-making processes, potentially affecting stakeholders and market perceptions.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Shareholder Meetings
Spire Healthcare’s 2025 AGM Resolutions Passed with Strong Support
Positive
May 14, 2025

Spire Healthcare Group PLC announced the successful passage of all resolutions at its 2025 Annual General Meeting, held on May 14, 2025. The results indicate strong shareholder support, with most resolutions receiving near-unanimous approval. This outcome reflects positively on the company’s governance and may enhance its position in the healthcare sector, potentially influencing investor confidence and future strategic decisions.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Spire Healthcare Reports Steady Performance and Strategic NHS Partnership
Positive
May 14, 2025

Spire Healthcare Group PLC reported that its performance from January to April 2025 aligned with expectations and the 2025 guidance, with a transformation program on track to deliver significant efficiencies. The company, which has full UK revenue exposure, does not foresee any major cost or supply chain issues due to recent tariff announcements. Additionally, Spire Healthcare has been named a founding supplier in the Government’s National Strategic Supplier Relationship programme, enhancing its collaboration with the NHS for sustainable NHS commissioning.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025